The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis

被引:8
|
作者
Lama, Niki [1 ]
Briasoulis, Alexandros [2 ]
Karavasilis, Efstratios [1 ]
Stamatelopoulos, Kimon [2 ]
Chasouraki, Angeliki [2 ]
Alexopoulou, Efthymia [1 ]
Spiliopoulos, Stavros [1 ]
Theodorakakou, Foteini [2 ]
Dimopoulos, Meletios Athanasios [2 ]
Kastritis, Efstathios [2 ]
Kelekis, Nikolaos L. [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Res Unit Radiol & Med Imaging, Dept Radiol 2, Med Sch,Fac Med, Papadiamantopoulou 19, Athens 11528, Greece
[2] Natl Kapodistrian Univ Athens, Fac Med, Med Sch, Dept Clin Therapeut, Vasilissis Sofias 80, Athens 11528, Greece
关键词
Amyloidosis; CMR; Spleen involvement; INTERSTITIAL VOLUME;
D O I
10.1186/s13244-022-01194-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives Cardiac magnetic resonance (CMR) imaging is a key test in the diagnosis of cardiac amyloidosis (CA). Extracardiac involvement is common in light chain (AL) amyloidosis and MRI findings may assist in its diagnosis. We sought to investigate the utility of splenic CMR parameters for the diagnosis of CA. Methods Thirty-four patients with AL amyloidosis and 32 patients with severe left ventricular hypertrophy in the setting of aortic stenosis (LVH-AS) who completed 3T cardiac MRI at the time of their diagnosis of AL or LVH-AS were assessed with T1, T2 (modified Look-Locker inversion recovery), extracellular volume (ECV) mapping, and late gadolinium enhancement (LGE) imaging of the heart and spleen. Results Age, left ventricular mass index, wall thickness, ejection fraction, and splenic dimensions did not differ significantly between groups. All AL patients had cardiac involvement. T1 and T2 spleen mapping did not differ significantly between groups but AL patients had higher median ECV in the spleen than in LVH-AS (AL 46.9%, LVH-AS: 31%, p < 0.001), and significantly lower short tau inversion recovery ratio (AL: 1.7, LVH-AS: 2.7, p < 0.001) both with very good diagnostic performance to diagnose AL. We identified 16 AL patients with spleen involvement and 16 without. Spleen ECV and "normalized" spleen ratio, defined as the ratio of spleen LGE to muscle values exhibited strong correlation and had excellent diagnostic performance to discriminate those with spleen involvement. Conclusion Our findings show that spleen CMR parameters can identify spleen involvement in AL patients and differentiate them from those without AL amyloidosis.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis
    Caccialanza, R
    Palladini, G
    Klersy, C
    Cena, H
    Vagia, C
    Cameletti, B
    Russo, P
    Lavatelli, F
    Merlini, G
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (02): : 350 - 354
  • [42] Novel Cardiovascular Magnetic Resonance Model to Distinguish Immunoglobulin Light Chain From Transthyretin Cardiac Amyloidosis
    Slivnick, Jeremy A.
    Tong, Matthew S.
    Nagaraja, Haikady N.
    Elamin, Mohamed B.
    Wallner, Alex
    O'Brien, Aaron
    Raman, Subha V.
    Zareba, Karolina M.
    JACC-CARDIOVASCULAR IMAGING, 2021, 14 (01) : 302 - 304
  • [43] The utility of cardiac magnetic resonance imaging in the diagnosis of cardiac sarcoidosis
    Stanton, Kelly
    Ganigara, Madhusudan
    Corte, Tamera
    Torzillo, Paul
    Celermajer, David
    Corte, Peter
    Puranik, Raj
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [44] The Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Cardiac Sarcoidosis
    Stanton, Kelly M.
    Ganigara, Madhusudan
    Corte, Peter
    Celermajer, David S.
    McGuire, Mark A.
    Torzillo, Paul J.
    Corte, Tamera J.
    Puranik, Rajesh
    HEART LUNG AND CIRCULATION, 2017, 26 (11): : 1191 - 1199
  • [45] Utility of cardiac magnetic resonance imaging in the diagnosis of cardiac sarcoidosis
    Madhusudan Ganigara
    Kelly Stanton
    Tamera Corte
    Peter Corte
    Paul Torzillo
    Raj Puranik
    Journal of Cardiovascular Magnetic Resonance, 16 (Suppl 1)
  • [46] Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis
    Grodin, Justin L.
    Anderson, Larry D., Jr.
    Kansagra, Ankit
    CIRCULATION, 2022, 145 (01) : 18 - 20
  • [47] Comparison of left ventricular global and segmental strain parameters by cardiovascular magnetic resonance tissue tracking in light-chain cardiac amyloidosis and hypertrophic cardiomyopathy
    Wang, Fangqing
    Xu, Xinghua
    Wang, Qing
    Yu, Dexin
    Lv, Lei
    Wang, Qian
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2023, 13 (01) : 449 - 461
  • [48] Light-chain cardiac amyloidosis with neuropathy: a case report
    Xu, Zhan-Wen
    Li, Ya-Qin
    Liu, Li-xia
    Zhou, Bing-Juan
    CLINICAL INTERVENTIONS IN AGING, 2015, 10 : 1219 - 1222
  • [49] MALNUTRITION AT DIAGNOSIS INDEPENDENTLY PREDICTS MORTALITY IN PATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS (AL)
    Caccialanza, R.
    Palladini, G.
    Klersy, C.
    Cereda, E.
    Bonardi, C.
    Quarleri, L.
    Merlini, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 355 - 355
  • [50] Nutritional status and quality of life in outpatients with systemic immunoglobulin light-chain amyloidosis (AL) at diagnosis
    Caccialanza, R.
    Palladini, G.
    Klersy, C.
    Bonardi, C.
    Cameletti, B.
    Cereda, E.
    Russo, P.
    Foli, A.
    Bragotti, L. Zenone
    Merlini, G.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2010, 17 : 172 - 173